This video has been sponsored by LivaNova.
Over the past two decades there have been several optimisation strategies, whether they are echo-guided or EKG-guided, aimed to improve outcomes in cardiac resynchronisation therapy (CRT) patients. However, none of them have worked very well. Experts believe that new results from the RESPOND-CRT global trial, published in the European Heart Journal, show that we have finally moved the needle using SonR technology, a cardiac contractility sensor from LivaNova, which delivers continuous individualised optimisation of resynchronisation therapy to heart failure patients. Jagmeet Singh (Boston, USA) and Angelo Auricchio (Lugano, Switzerland) discuss the technology behind sensor-based CRT optimisation and why this strategy is different. To learn more, please click here
